Back
Alimera Sciences 10K Form
Buy
61
ALIM
Alimera Sciences
Last Price:
5.54
Seasonality Move:
-13.1%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-14 | 10Q | ALIM/Alimera Sciences Quarterly |
| 2023-11-02 | 10Q | ALIM/Alimera Sciences Quarterly |
| 2023-08-11 | 10Q | ALIM/Alimera Sciences Quarterly |
| 2023-05-15 | 10Q | ALIM/Alimera Sciences Quarterly |
| 2022-11-14 | 10Q | ALIM/Alimera Sciences Quarterly |
| 2022-08-05 | 10Q | ALIM/Alimera Sciences Quarterly |
Receive ALIM News And Ratings
See the #1 stock for the next 7 days that we like better than ALIM
ALIM Financial Statistics
Sales & Book Value
| Annual Sales: | $80.75M |
|---|---|
| Cash Flow: | $915K |
| Price / Cash Flow: | 0 |
| Annual Sales: | $0.74 |
| Price / Book: | 7.77 |
Profitability
| EPS (TTM): | -0.31000 |
|---|---|
| Net Income (TTM): | $-14.7M |
| Gross Margin: | $69.92M |
| Return on Equity: | -33.3% |
| Return on Assets: | -9.6% |
Alimera Sciences Earnings Forecast
Key Alimera Sciences Financial Ratios
- The Gross Profit Margin over the past 18 years for ALIM is 86.58%.
- The Selling, General & Administrative Expenses for ALIM have been equal to 57.55% of Gross Profit Margin.
- The Research & Development expenses have been 20.59% of Revenue.
- The Interest Expense is -50.59% of Operating Income.
- The Net Earning history of ALIM is -24.93% of Total Revenues.
- Per Share Earnings over the last 18 years have been positive in 13 years.
Alimera Sciences Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Current Symbol: | ALIM |
| CUSIP: | 016259 |
| Website: | alimerasciences.com |
Debt
| Debt-to-Equity Ratio: | 1.8 |
|---|---|
| Current Ratio: | 2.79 |
| Quick Ratio: | 2.41 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 23.08 |
ALIM Technical Analysis vs Fundamental Analysis
Buy
61
Alimera Sciences (ALIM)
is a Buy
Is Alimera Sciences a Buy or a Sell?
-
Alimera Sciences stock is rated a Buy
The current Alimera Sciences [ALIM] share price is $5.54. The Score for ALIM is 61, which is 22% above its historic median score of 50, and infers lower risk than normal.